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age of the patients was 55.95 yrs, of which 89.58 %weremales. The
average weight was 72.67 kg. The indications for PCI were 46.18 %
Unstable angina, 20.72% NSTEMI and 33.10% STEMI. 86.92% pa-
tients took a loading dose of 60 mgs whereas 13.08% patients who
had taken loading dose of clopidogrel were given only mainte-
nance dose of 10 mgs/day. A total of 26 adverse events were
noticed. Preliminary analysis revealed death of 2 patients due to
possible stent thrombosis. Three patients required revasculari-
zation (1 for stent thrombosis & 2 others for a different vessel
intervention) and 1 required rehospitalisation however for a non
cardiac cause. Major bleeding was seen in 1 patient whereas 19
patients experienced minor bleeds.
Comparison of clopidogrel vs prasugrel in patients
going for PCI-2 year follow-up
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Background: There has been no Indian data on the efficacy and
safety of prasugrel VS clopidogrel.
Aim: To compare the efficacy and safety of prasugrel with that of
clopidogrel in patients who underwent PCI.
Methods: This is a retrospective observational study. We collected
the data from patients who underwent elective/emergency PCI and
were given prasugrel and clopidogrel. The studywas between 2010-
2012. 235 patients formed the cohort. Group I consisted of 129 pa-
tients who were treated with clopidogrel and group II was of 106
patients treated with clopidogrel. Prasugrel group received loading
doseof (LD)60mg followedbymaintenancedose (MD)of 10mgonce
daily. LD and MD of clopidogrel was variable. We collected and
analysed the baseline characteristics and in hospital , 30 days, 6
months, 18 months and 24 months major adverse vascular events.
Primary end point was composite of death, ACS, stroke, emergency
revascularisation, stent thrombosis, major bleeding. Individual
secondary end points considered were admission for CCF, stent
thrombosis, instent restenosis, minor bleed, hospital stay and ACS.
Results: Mean age and sex distribution were similar in both the
groups. Dyslipidemia, hypertension, family history, two vessel
disease were higher in group II. More patients in group II had past
history of MI, prior PCI and CABG .STEMI numbers were high in
group I. Group I had significantly more primary PCI and use of GP
IIB III a blocker . In hospital complications were comparable in
both the groups. There was no significant difference between the
groups in the composite primary end points during the entire
follow up period. ACS was the only secondary endpoint that
occurred significantly in group 2 (p 0.03).
Conclusion: The efficacy and safety of prasugrel was comparable
to that of clopidogrel in our study. Occurrence of ACS was
significantly more in prasugrel group.
Acute coronary syndrome in very young adults
(<35 yrs) e Time to awake and act !
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Background: Acute Coronary syndrome in very young adults
(<35yrs) was considered as an uncommon entity, recently shows
rising incidence especially in India. ACS in this younger age is not,
simply a problem of sufferers but a huge emotional and
economical loss to the family.
Materials and Methods: This is a prospective analytical study
included patient <35yrs with ACS admitted in GovtRajajihospital
(Madurai Medical College) in TamilNadu during Jan2013 to June
2014. Risk factors, clinical, angiographic profile and follow up data
were recorded and analyzed.
Results: Among the total 2180 patients with ACS, 5.8 % (n¼127)
were very young adults. Youngest one was 11 yrs old with coro-
nary anomaly. Mean age was 29.7yrs (±3.7) and only 8.6% (n¼10)
were obese. Patients reached the hospital with median delay of
7hrs.Smoking (85%), male sex (93.9%) were the major conven-
tional risk factors followed by low HDL (52%). Family history of
premature coronary event seen in 12.9%, hyperhomocysteinemia,
elevated Lpa and high fibrinogen were observed in 15%, 20% &
3.5% respectively. Anteriorwall MI with LAD occlusion was the
commonest type (66.3%). Only 2 were undergone primary PCI
(1.7%), 61% (n¼71) received thrombolytic therapy. Median delay
for angiogram was 72hrs (3 days). Angiographically majority
(53.4%) had SVD, 31% had recanalised vessels. Coronary anomaly
was seen in 4 (3.4%) patients and pure ectasia in 3 (2.5%) patients.
Mean EF was 42% (±7). In hospital mortality was 3.4% and 4.5 %
(n¼5) during followup.
Conclusion: Our observation showed, obstructive CAD in 56.9% of
young ACS patients (<35yrs). This rapid progression of athero-
sclerosis in Indians is not simply due to conventional risk factors
alone but due to complex interaction of both conventional and
novel risk factors. Significant admission and therapeutic delay
implicate the need of active strategies to protect these budding
adults.
Study of factors associated with delayed
thrombolysis and its impact on mortality and
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Background: Treatment delay in the management of STEMI /
NSTEMI inversely correlates with prognosis and survival of the
patients. This study was aimed to investigate factors associated
with delay in the thrombolytic therapy of these patients in a
municipal teaching hospital.
Methods: Data was collected prospectively of all patients who
were admitted with acute myocardial infarction from March 2014
e June 2014. Old myocardial infarction / old coronary artery
bypass graft surgery/old percutaneous transluminal coronary
angioplasty (PTCA) patients were excluded. The cardiology regis-
trar in casualty initially filled the questionnaire and sent it to the
cardiology registrar in ICCU. The cardiology registrar on duty in
ICCU completed the questionnaire at discharge. The question-
naire comprised of age, gender, weight, address, presenting
symptoms, chest pain type, onset, events between chest pain
onset and presentation to hospital, time between symptom onset
and presentation to hospital, mode of transport to hospital, risk
factors- smoking/diabetes/hypertension/dyslipidemia /family
history , previous history of angina, socioeconomic status,
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educational status, killips class on admission, blood pressure on
admission, heart rate on admission (sinus rhythm), arrhythmias,
contraindication to thrombolytic therapy, STEMI / NON STEMI, Q
waves on admission, infarct location, pain to needle time, pain to
door time, door to needle time, ecg evidence of early reperfusion,
in hospital outcome edeath/further deterioration, functional
status at discharge, left ventricular ejection fraction at discharge,
mitral regurgitation at discharge.
Results: Total 204 patients were studied, out of which 198 patients
were thrombolysed. The results of which are as follows: out of 198
patients studied 164 (82.8%) were males and 34 (17.17%) were fe-
males. Most common age group of presentationwas 50-75 yrs. The
mean time of delayed presentation was found to be 4.5 hrs. The
delay to hospital was more in 50-75yrs age group (p value <0.05).
The delay was more in the diabetic patients as compared to the
patients without diabetes (p value<0.01). Patients with past his-
tory of angina, onset of symptoms in the early morning and late
night, low socioeconomic & low educational status was signifi-
cantly associated with delay of more than two hours in seeking
hospital care (p value< 0.05). The incidence of mortality, heart
failure, fatal arrhythmias, lower ejection fraction, acute kidney
injury, mitral regurgitation was more in patients presenting after
two hours.
Conclusion: The result of this study suggests that a large propor-
tion of patients with acute myocardial infarction continue to
exhibit delay in hospital presentation. The characteristic of many
of these individuals can be identified in advance for targeted
educational efforts.
Prognostic value of BNP levels in acute coronary
syndromes
Vicar Jan, Nadeem Sheikh, Hilal Rather, Imran Hafeez,
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Background: Brain (B-type) natriuretic peptide is a neurohormone
synthesised predominantly by the ventricular myocardium.
Although initially BNP levels were used in the diagnosis of acute
heart failure, the circulating hormone has been shown to provide
independent prognostic value in patient with acute coronary
syndromes.
Method: This study comprised of prospective analysis of 50 pa-
tients of acute coronary syndromes (37 STEMI, 10 NSTEMI and 3
UA) admitted within 72hours of the event. The purpose of the
study was to study the effects of high admission BNP levels on
mortality and morbidity of patients at 30 days and at 6 months.
Results: The baseline level of B - type natriuretic peptide was
correlated with the risk of death, heart failure and death at 30 days
and at 6months. Among 50 patients, 21 patients whose admission
BNP levels were <¼80 pg/ml death occurred in 1 patients, CCF in 4,
NewMI in 7 and none in 9 patients occured at 30 days, and among
29 patients whose admission BNP levels were > 80 pg/ml, death
occured in 4 patients, CCF in 08 patients, New MI in 15 patients
and no complications was seen in 2 patients.(p value¼0.024).
At 6 months 21 patients whose admission BNP Levels were <¼
80 pg/ml death occured in 01 patients, CCF in 05 patients, New MI
in 08 patients and in 7 patients no complication was observed and
among 29 patients whose admission BNP levels were > 80 pg/ml,
death occured in 05 patients, CCF in 08 patients, New MI in 16
patients and none was observed in 0 patients.(p value¼0.007).
Conclusion: A single measurement of BNP levels obtained within
first few days after the onset of ischemic symptoms, provide
predictive information for use in risk stratification across spec-
trum of acute coronary syndromes.
A multicentric, retrospective, outcome analysis of
contemporary antiplatelet discontinuation
practices in coronary artery disease patients
undergoing cardiac / non cardiac surgeries
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Fortis Escorts Hear Institute, Fortis Vasant Kunj Hospital, India
Background: Patients with coronary artery disease (CAD) poses
cardiologists, surgeons, and anesthetists with the dilemma of
deciding between the risk of increased blood loss when
continuing antiplatelet agents in the perioperative period, and the
risk of thromboembolic events if the drugs are stopped.
Aim: Analysis of the data, on the current practices of continuation
or discontinuation of anti-platelets in CAD patients undergoing
cardiac/non-cardiac surgery. In addition to observe adverse
events resulting from this practice.
Methods: Multi centric, retrospective, observational study con-
ducted in three tertiary care centers of India. A minimum 1537 pa-
tients with CAD undergoing surgeries will be included in the study.
ThePrimaryoutcomeof thestudy isperi-operative thromboembolic
events - stroke, pulmonary embolism, deep vein thrombosis and
acute coronary syndromes and the secondary outcome is Peri-
operativebleeding.Bleedingwasclassifiedasmajor (Type2 to5) and
minor (Type 0 and 1) as per the BARC definition of bleeding.
Results: In this ongoing study 513 patients have been enrolled.
The average age of the patients was 62 yr out of these 85.4% were
male. 414 (80.7 %) of patient underwent cardiac surgery and 99
(19.3%) patient underwent noncardiac surgery.
Of the patient who underwent cardiac surgery 352 (85 %) dis-
continued the anti platelet therapy while 40 (40.4 %) underwent
non cardiac surgery after discontinuing antiplatelets.
In cardiac surgery patient population , major bleeding occurred
in 6.0% in discontinuation group vs 3.2 % of patients in continu-
ation group (p ¼ 0.302). In non cardiac surgery population, major
bleeding were nil in both continuation and discontinuation group.
Conclusion: Antiplatelet was discontinued more often in patients
who underwent cardiac group. There was no significance in the
bleeding. Thrombotic events were not influenced by discontinu-
ation of antiplatelets.
Impact of atropine and aminophylline on
atrioventricular block after acute inferior wall
myocardial infarction
S.K. Dwivedi, Pankaj Kumar, V. Singh, R.K. Saran, S. Chandra,
G. Chaudhary, A. Pradhan, R. Sethi, V.S. Narain
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Background: Intravenous (IV) aminophylline has been anecdotally
shown to improve conduction in atrio-ventricular (AV) block after
acute myocardial infarction (AMI).Present study tried to see the
efficacy of aminophylline in patients (pts.) who did not respond
with atropine.
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